All News
Filter News
Found 808,991 articles
-
Persona™ Expands its Drug-Nutrient Interaction Database, Cross-Examining More Than 1,000 Prescription Medications
9/16/2019
Persona™, a leading personalized vitamin subscription program, today announced the expansion of its drug nutrient interaction (DNI) database to deliver a truly personalized approach to wellness.
-
DiamiR Announces Additional $345,000 Funding from the NIH for Development of CogniMIR™
9/16/2019
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded DiamiR $345,000 in supplemental funding under the ongoing Small Business Innovation Research (SBIR) Phase IIB grant of $2,800,000 awarded in 2017.
-
Neovasc Announces Changes to its Board of Directors
9/16/2019
Norman Radow, Managing Partner at Strul Medical Group, Joins Company's Board
-
FDA Grants Fast Track Designation for FARXIGA in Heart Failure
9/16/2019
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
-
Researchers Present New Data on the Utility of Genomind's Mental Health Pharmacogenomic Testing at Upcoming Scientific Conferences
9/16/2019
Genomind®, a leading mental health company bringing precision medicine into mainstream mental health treatment, announced today that four abstracts in which Genomind's pharmacogenomic test was utilized to direct mental health pharmacotherapy have been accepted for presentation at upcoming medical conferences.
-
Mentice Introduces its Advanced, High-fidelity VIST® One TEE Echocardiography Training Solution at TCT Symposium 2019
9/16/2019
Featuring real-time 2D and 3D echo and multiplanar reconstruction, VIST® One TEE is the most sophisticated TEE Training solution available in the market today.
-
Controlant Announces Participation in Fall Life Sciences Supply Chain Events
9/16/2019
Controlant, a leading provider of next-generation visibility solutions for digitally connected temperature-controlled supply chains, today announced its participation in the upcoming LogiPharma US and the Cold Chain Global Forum Life Sciences events.
-
Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society
9/16/2019
Intec Pharma Ltd. announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa, will be presented at the upcoming International Congress of Parkinson's and Movement Disorder Society being held from September 22-26, 2019 in Nice, France.
-
VALBIOTIS Presents Positive Results From a Study on TOTUM-63, Active Substance of VALEDIA®, Conducted by the CarMeN Laboratory in Lyon, at the Annual Meeting of the European Association for the Study of Diabetes (EASD)
9/16/2019
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the presentation of a preclinical study conducted by the CarMeN laboratory on the active substance TOTUM-63, at the 55th Annual Meeting of the European Association for the Study of Diabetes being held September 16-20, 2019
-
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
9/16/2019
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.
-
BevCanna Announces Exclusive Supply Agreement with Nextleaf Solutions for Water-Soluble Cannabinoids
9/16/2019
Two Canadian companies well-positioned for early market leadership within infused product landscape.
-
SofWave Medical's Low-divergence Ultrasound Technology Has Received FDA Clearance for the Aesthetic Treatment of Facial Lines and Wrinkles
9/16/2019
Sofwave Medical Ltd., an emerging aesthetic device company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Sofwave system
-
Zimmer Biomet Receives FDA Clearance of JuggerStitch™ Meniscal Repair Device
9/16/2019
The Next Generation Of This Pioneering Meniscal Repair Technology
-
The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
9/16/2019
A total of $1.3 million awarded to advance early detection and new treatments for kidney cancer
-
Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment
9/16/2019
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment.
-
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac™ Individualized Immunotherapy TG4050
9/16/2019
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces it has received approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with two Phase 1 clinical trials of its lead myvac™ candidate TG4050.
-
Sante Cannabis and Spectrum Therapeutics Launch Transformative Medical Cannabis Training Program for Quebec Healthcare Professionals
9/16/2019
Prescriber Training Program is designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.
-
ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit
9/16/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that Executive Chairman, Eugene Williams will participate on an executive panel at the Fall Investor Summit being held today at noon at the JW Marriot Essex House
-
hyperCORE International Teams with VirTrial to Become First ‘Virtual Trial Capable’ Site Network in the World
9/16/2019
hyperCORE includes more than 80 sites across five countries and two continents and is the first site network to have all sites trained and certified as Virtual Trial Capable.
-
The Lancet to Publish Study that Shows Hyperkalemia Drug May Help Kidney Patients Stay on Treatment for Hypertension
9/16/2019
Results presented at late-breaking trial session of National Kidney Foundation's 2019 Spring Clinical Meetings